Colorectal Cancer News and reporting on colorectal cancer. Jan 20, 2023 FDA Approves Seagen's Tukysa, Genentech's Herceptin for HER2-Positive Colorectal Cancer Patients Jan 19, 2023 Colorectal Cancer Detection Data from CellMax Life Bodes Well for Planned FDA Bid Premium Jan 19, 2023 Guardant Health, Royal Marsden Partner on Prospective Liquid Biopsy Trial in Early Colorectal Cancer Jan 17, 2023 Elicio Therapeutics to Merge With Angion Biomedica Jan 11, 2023 Bio4t2 Begins Dosing Solid Tumor Patients in First-In-Human CAR T-Cell Therapy Trial Jan 10, 2023 Immunocore Unveils New T-Cell Receptor Therapy Candidates, Estimates $140M in 2022 Kimmtrak Sales Dec 20, 2022 Multiomic Study Points to New Colorectal Cancer Risk Contributors Dec 16, 2022 Guardant Health CRC Screening Results Spook Investors Despite Meeting Reimbursement Requirements Dec 1, 2022 Sofie Biosciences to Begin Trial of Fluorine-Labeled PET Diagnostic Imaging Agent for GI Cancers Nov 30, 2022 Addario Lung Cancer Medical Institute Begins Study Exploring KRAS Inhibitor Resistance Nov 30, 2022 Erasca Inks Deal With Pierre Fabre on ERAS-007, Braftovi Combo Study in Colorectal Cancer Nov 30, 2022 Personalis, UCSF to Study ctDNA Utility in Colorectal Cancer Treatment Response Monitoring Nov 29, 2022 Alaunos Therapeutics Expecting $15.7M in Common Stock Offering Nov 15, 2022 Nouscom Begins Phase II Trial of Neoantigen-Targeted Cancer Vaccine With Checkpoint Inhibitor Nov 9, 2022 GastroIntestinal Research Foundation to Fund Personalized Vaccine, Immunotherapy Research Nov 4, 2022 Lumakras Sales More Than Double in Q3 2022 as Amgen's Overall Revenues Decline 1 Percent Premium Oct 26, 2022 Yale Spinout Modifi Biosciences Nets $2.4M From NCI to Advance Targeted Cancer Drugs Toward Clinic Oct 24, 2022 Zentalis Pharma to Begin ZN-c3 Combo Study in BRAF V600E-Mutant Colorectal Cancer Oct 21, 2022 Erasca to Study ERK Inhibitor With Pfizer's Ibrance in Tumors Harboring KRAS, NRAS Mutations Oct 19, 2022 Craig-Hallum Initiates Coverage of Guardant Health With Buy Rating Load More Breaking News Ratio Therapeutics Raises $20M in Series A Financing Guardant Health, AnHeart Tx to Develop Blood- and Tissue-Based CDx for NSCLC Drug Ellipses Pharma Cleared by FDA to Open Phase I/II AML Trial Survey Reveals Changing Genetic Testing Patterns, Persistent Disparities in Precision Oncology Amgen's Lumakras Sales Increased 58 Percent in Q4 2022 Coeptis Therapeutics, University of Pittsburgh Studying SNAP-CAR Therapy in HER2-Positive Cancers
